Dr. Clay Siegal founded Seattle Genetics, which is a biotech firm committed to the development cancer-related therapies in 1998. He serves on the company’s board as the Chairman, Chief Executive Officer, and President. Dr. Siegal is a scientist by profession and specializes in targeted cancer therapies. Dr. Clay Siegal built his biotech firm on a foundation of drug development, scientific innovation, and rigorous research. His primary mission is to help patients afflicted by ultra-rare disorders. Over time, Clay Siegal has led Seattle Genetics to its current position in cancer treatment space. He initiated the development of the firm’s first antibody-drug conjugate and the approval of ADCETRIS in 2011.
Under his leadership, ADCETRIS has grown to become a global brand with approval in over 65 nations around the globe. Seattle Genetics is also working on the development of a broad array of proprietary ADCs for cancer treatment. During the tenure of Dr. Clay Siegal, Seattle Genetics has arrived at several strategic partnerships for its innovation in the world of cancer treatment. Its collaboration with AbbVie, Genentech, and Pfizer has helped raise over $350 million. Over 20 ADCs in clinical development are currently using the innovative technology of Seattle Genetics. Dr. Clay Siegal has also assisted Seattle Genetics in capital raising, generating over $1.2 billion in private and public financing. In 2011, the firm used its initial public offering to raise working capital.
Dr. Clay Siegal would work for the Bristol-Myers Squibb Pharmaceuticals between 1991 and 1997 before founding Seattle Genetics. He also worked at the National Institute of Health as well as the National Cancer Institute between 1988 and 1991. Despite his busy schedule at Seattle Genetics, Dr. Clay Siegal is a board member of Washington Roundtable and Ultragenyx Pharmaceuticals. He has earned numerous awards for his excellence in cancer space. Some of his awards include the 2012 Pacific Northwest Ernst & Young Entrepreneur Award and the Alumnus of the Year Award from the Maryland University. Over time, Dr. Siegal has authored close to 70 peer-reviewed cancer-related publications. He went to the University of Maryland where his relentless efforts earned him a BS in Zoology.
Mikhail Blagosklonny is a man of ample intellect and expertise. He is a professor, scientist, and expert. Mr. Blagosklonny’s educational background is rather impressive and extensive. Mikhail BLAGOSKLONNY holds both a M.D. and a PhD. He has an M.D. in internal medicine and a PhD in experimental medicine and cardiology. He has utilized knowledge from both degrees in his work as a scientist. Mikhail’s alma mater is First Pavlov State Medical University of St. Petersburg. Mr. Mikhail has applied his educational knowledge to a few roles as associate professor and professor. His professional background includes a role as associate professor at New York Medical College. He later became senior scientist at Ordway Research Institute, and following his role as senior scientist he became professor of oncology at Roswell Park Cancer Center. During his professional involvements he has also conducted extensive research on the topics of cancer therapy and anti-aging. He has over 270 research articles in peer-reviewed journals. Visit ResearchGate to keep up to date with Mikhail’s latest work.
In addition to his role as educator and scientist Mikhail Blagosklonny provides editorial services. His editorial achievements include his role as editor-in-chief of Aging, Cell Cycle, and Oncotarget. He has served a role as associate editor of Cancer Biology and Therapy, and he is a member of the editorial board of Cell Death and Differentiation. Mr. Mikhail is a productive man with extreme scholarly involvement. Although every editorial role is valuable Mr. Mikhail is perhaps most known for OncoTarget. Oncotarget is a multidisciplinary peer-reviewed journal. It provided free access and produces multiple articles a week. Founders desire to make information easily accessible.
Mikhail Blagosklonny researches topics that many individuals of society have interest in today. This includes the topic of anti-aging. Anti-aging has been an area of much interest, funding, and research. One need not question why. Finality and death is one of the few issue of humanity society is yet to remedy. However, Mr. Mikhail is searching anti-aging methods. In his article ” Rejuvenating immunity: ” anti-aging drug today” eight years later”, he discussed past research, progress, and concerns. In this article Mr. Blagosklonnny discusses previous criticisms of a TOR- centric model and the results found from the model. TOR, also known as Target of Rapamycin, uses rapamycin to treat aging and prevent disease. If used consistently with the proper dosage it can extend the healthy life-span of a human. Although the TOR- centric model can help extend the overall life-span it cannot completely eliminate death. Unknown disease is likely to come along at some point leading to fatality. These are amazing and exciting findings! Mikhail Blagosklonny has proven to produce informational, productive, and insightful research. Through the marriage of his knowledge about aging and oncology Mikhail works to find a way to eliminate the process of aging related to cancer.
Mikhail Blagoskonnny is using his knowledge to make a positive difference in the world, and his research may one day change humanity as we know it. Mr. Blagoskanny attributes his drive and interest to a desire for a healthy and disease free community.